



# Simplifying complexity in clinical trials

Accelerate your trials with confidence

CLARIO.

## Assess efficacy, safety and quality of life with a single, proven vendor


Biotech companies face immense challenges in drug development – rising costs, regulatory complexities and the critical need for high-quality data. At Clario, we simplify these complexities with a full suite of digital endpoint solutions and have supported over **60%** of all new FDA drug approvals since 2012.



## Comprehensive digital endpoint solutions

Our solutions provide consistent, accurate data to assess efficacy, safety and quality of life across all key modalities:

- **eCOA:** Seamlessly capture how your participants are feeling and functioning with flexible in-clinic and remote electronic Clinical Outcome Assessments (eCOAs), delivering informative data that are ready for review in real time.
- **Cardiac:** Capture precise cardiac safety and efficacy data with advanced ECG, arrhythmia and blood pressure monitoring solutions while also benefiting from our expert scientific consulting services.
- **Respiratory:** Ensure accurate pulmonary function assessments with centralized spirometry and advanced diagnostics supported by specialist biotech teams.
- **Imaging:** Generate high-quality imaging data with deep expertise across MRI, CT, PET and ultrasound alongside advanced workflows for blinded, independent centralized data analysis.
- **Clinical adjudication:** Streamline complex endpoint assessments with a centralized, compliant adjudication process.



## Scientific expertise that drives success

Behind every trial is a need for scientific precision. Clario's team of 125+ full-time medical and scientific experts across all therapeutic areas enables:

- Optimized trial design aligned with regulatory expectations.
- Rigorous data interpretation for enhanced decision-making.
- Participant-centric strategies to improve recruitment, engagement and retention.

## Operational excellence to keep you on track

Our global operational teams are highly coordinated, specialized and agile. We offer:

- Concierge-level project management tailored for biotech needs.
- Rapid scalability to meet your trial milestones.
- On-time delivery of devices to support your trials globally.

## Cutting-edge technology for smarter trials

Our next-generation technology empowers biotech companies with:

- **AI-driven analytics:** Advanced algorithms that enhance data precision and efficiency.
- **Single sign-on access:** A seamless, secure platform for managing all endpoint solutions.
- **24/7 customer support:** Comprehensive, multilingual support globally to keep your trials running smoothly.

## Proven impact: A partner you can trust


Clario has supported over **60% of FDA new drug approvals since 2012**. Our track record speaks to the trust biotech companies place in us to deliver accurate, regulatory-compliant data that can accelerate approvals and reduce trial risk.

## Your partner in innovation

At Clario, we don't just provide data – we provide **confidence**. Our integrated solutions, expert teams and advanced technology work together to help you navigate the complexities of clinical trials with certainty. Let's move forward together.



Learn more about how Clario can support your biotech trial. Visit [clario.com](https://clario.com) or contact us today.



## About Clario

Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for life sciences companies. We offer comprehensive evidence-generation solutions that combine medical imaging, eCOA, precision motion, cardiac and respiratory endpoints.

For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have been deployed over 26,000 times to support clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012.